Skip Navigation

Nephrology Dialysis Transplantation 2005 20(4):811-816; doi:10.1093/ndt/gfh656
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Takenaka, T.
Right arrow Articles by Suzuki, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takenaka, T.
Right arrow Articles by Suzuki, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org


Preliminary Communication

New strategy to attenuate pulse wave velocity in haemodialysis patients

Tsuneo Takenaka1 and Hiromichi Suzuki2

1 Shinjuku Suimei Clinic, Shinjuku, Tokyo and 2 Department of Medicine, Saitama Medical College, Iruma, Saitama, Japan

Correspondence and offprint requests to: Hiromichi Suzuki, MD, Saitama Medical College, Department of Medicine, 38 Moro-hongo Moroyama, Iruma, Saitama 350-0495, Japan. Email: iromichi{at}saitama-med.ac.jp

Background. Pulse wave velocity (PWV) is commonly elevated in haemodialysis (HD) patients having cardiovascular diseases. Disturbances in calcium–phosphate metabolism are among the established cardiovascular risk factors in HD patients. The present study was performed to assess the effect of sevelamer on PWV in HD patients.

Methods. Fifteen patients, who had been treated with calcium carbonate as a phosphate binder, were entered into the study. Changes in PWV during the 6 months before sevelamer administration were compared with PWV changes during 6 months of receiving sevelamer. Serum biochemistry parameters were also assessed.

Results. Compared with the preceding control period, the sevelamer period resulted in decreased serum calcium (9.9±0.1 to 9.6±0.1 mg/dl, n = 15; P<0.01) in association with reductions in oral calcium load (4.3±0.4 to 2.3±0.6 g/day; P<0.001). Serum phosphorus and whole parathyroid hormone remained unchanged. Sevelamer reduced serum total cholesterol (167±7 to 148±6 mg/dl; P<0.001) and LDL-cholesterol (85±8 to 65±7 mg/dl; P<0.001), without modifying HDL-cholesterol or triglycerides. Finally, sevelamer reversed the increase in PWV observed during the control period (from 46±16 to –20±9 cm/s/month; P<0.01).

Conclusions. In chronic HD patients, sevelamer decreased serum total- and LDL-cholesterol as well as calcium. Moreover, our findings suggest that treatment with sevelamer attenuates the progressive increase in PWV observed during calcium carbonate treatment.

Keywords: blood pressure; calcium overload; dyslipidaemia; hyperphosphataemia; parathyroid hormone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
HeartHome page
C J Ferro, C D Chue, R P Steeds, and J N Townend
Is lowering phosphate exposure the key to preventing arterial stiffening with age?
Heart, November 1, 2009; 95(21): 1770 - 1772.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
S. S. DeLoach and R. R. Townsend
Vascular Stiffness: Its Measurement and Significance for Epidemiologic and Outcome Studies
Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 184 - 192.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. Covic, N. Mardare, P. Gusbeth-Tatomir, O. Prisada, R. Sascau, and D. J. A. Goldsmith
Arterial wave reflections and mortality in haemodialysis patients--only relevant in elderly, cardiovascularly compromised?
Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2859 - 2866.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.